Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | SORD | Q00796 | 2/20 | 0.43 |
| ▸ | GBA1 | P04062 | 7/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12986688 | 0.96 | GBA1 (0.47) | KMT2ASORDGBA1KDM4EMEN1 | |
| SCHEMBL12141944 | 0.95 | GBA1 (0.46) | KMT2ASORDGBA1KDM4EMEN1 | |
| SCHEMBL18068014 | 0.89 | SORD (0.51) | KMT2ASORDKDM4EMEN1HSD17B10 | |
| SCHEMBL11960321 | 0.85 | KMT2A (0.64) | KMT2AKDM4EMEN1HSD17B10NPSR1 | |
| SCHEMBL12986289 | 0.85 | CASP1 (0.47) | KMT2ASORDKDM4EMEN1USP2 | |
| SCHEMBL12990426 | 0.85 | SORD (0.47) | KMT2ASORDGBA1KDM4EMEN1 | |
| SCHEMBL13033934 | 0.82 | KMT2A (0.56) | KMT2ASORDGBA1KDM4EMEN1 | |
| SCHEMBL12986274 | 0.82 | KDM4E (0.50) | KMT2ASORDKDM4EMEN1HSD17B10 | |
| SCHEMBL12986291 | 0.81 | SORD (0.44) | KMT2ASORDGBA1KDM4EMEN1 | |
| SCHEMBL12986269 | 0.80 | GBA1 (0.63) | KMT2ASORDGBA1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179782-B2 | Substituted sulfonamide compounds | GENENTECH, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-8486950-B2 | Janus kinase inhibitor compounds and methods | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-16 | — | — | US | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179782-B2 | Substituted sulfonamide compounds | TRPA1, TRPV1, TRPV5 | KMT2A 3258/4885SORD 1498/4885GBA1 309/4885 |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | KMT2A 939/4885SORD 4493/4885GBA1 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.